Current Research Studies
Phase 2 Randomized, Double-blind, Placebocontrolled, Study of Zatolmilast (BPN14770) in Subjects with PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome)
Jordan's Syndrome Clinical Trial
What is the goal of the study?
This is a multi-center, Phase 2, randomized, double-blind, placebo-controlled, study with an open label extension to obtain preliminary assessment of the effects of zatolmilast in patients with PPP2R5D neurodevelopmental disorder.
Who can participate in the study?
Please contact the study team listed below to learn more.